Appendix 4E - Preliminary Final Report
Released
Released
Announcement PDF
Avecho Biotechnology Limited
ABN 32 056 482 403
Preliminary Final Report - 31 December 2024
Avecho Biotechnology Limited
Appendix 4E
Preliminary final report
1. Company details
Name of entity:
ABN:
Reporting period:
Previous period:
Avecho Biotechnology Limited
32 056 482 403
For the year ended 31 December 2024
For the year ended 31 December 2023
2. Results for announcement to the market
$
Revenues from ordinary activities
up
139.2% to
1,132,672
Loss from ordinary activities after tax attributable to the owners of Avecho
Biotechnology Limited
down
9.2% to
(3,122,048)
Loss for the year attributable to the owners of Avecho Biotechnology
Limited
9.2% to
(3,122,048)
down
The loss for the Consolidated Entity after providing for income tax amounted to $3,122,048 (31 December 2023: $3,436,561).
Explanation of loss from ordinary activities after tax
Total revenue increased by 139% for the 2024 financial year to $1,132,672 (31 December 2023: $473,551), primarily due to
increase in Vital ET® sales when compared to the 2023 financial year.
Other income increased to 62% to $1,893,782 (31 December 2023: $1,167,984), primarily due to higher R&D tax incentives
of $1,635,464 (31 December 2023: $1,075,567). The increase in the research and development activities during 2024 financial
year compared to 2023 financial year was due to the Phase III Clinical Trial evaluating the efficacy of its oral cannabidiol
capsule for the treatment of insomnia, which commenced during the 2024 financial year.
Expenses from continuing operations, excluding cost of sales, increased 25% to $5,687,756 (31 December 2023: $4,560,750),
primarily due to higher research and development costs of $3,591,156 (31 December 2023: $2,117,263).
At 31 December 2024, the Consolidated Entity held $2,374,534 in cash and cash equivalents (31 December 2023:
$5,504,396). The net assets of the Consolidated Entity decreased by $3,108,032 to $3,269,738 as at 31 December 2024 (31
December 2023: $6,377,770), largely due to the ongoing investments in Phase III Clinical Trial. Working capital, being current
assets less current liabilities, was $3,099,882 as at 31 December 2024 (31 December 2023: $6,160,327).
The net operating cash outflow for the year was $3,968,718 (31 December 2023: outflow $3,179,955), resulting from the
operations of the Consolidated Entity.
3. Net tangible assets
Reporting
period
Cents
Net tangible assets per ordinary security
0.10
4. Control gained over entities
Not applicable.
1
Previous
period
Cents
0.20
Avecho Biotechnology Limited
Appendix 4E
Preliminary final report
5. Loss of control over entities
Not applicable.
6. Dividends
Current period
There were no dividends paid, recommended or declared during the current financial year.
Previous period
There were no dividends paid, recommended or declared during the previous financial year.
7. Dividend reinvestment plans
Not applicable.
8. Details of associates and joint venture entities
Not applicable.
9. Foreign entities
Details of origin of accounting standards used in compiling the report:
Not applicable.
10. Audit details
Details of audit:
The financial statements are currently in the process of being audited by Grant Thornton Audit Pty Ltd. The Company expects
to receive an unqualified audit opinion.
11. Attachments
Details of attachments (if any):
Preliminary Final Report of Avecho Biotechnology Limited for the year ended 31 December 2024 is attached.
12. Signed
Signed ___________________________
Date: 28 February 2025
Dr Gregory Collier
Chairman
2
Avecho Biotechnology Limited
Contents
31 December 2024
Consolidated statement of profit or loss and other comprehensive income
Consolidated statement of financial position
Consolidated statement of changes in equity
Consolidated statement of cash flows
Notes to the consolidated financial statements
3
4
5
6
7
8
Avecho Biotechnology Limited
Consolidated statement of profit or loss and other comprehensive income
For the year ended 31 December 2024
Consolidated
31 December 31 December
Note
2024
2023
$
$
Revenue from contracts with customers
Cost of sales (including impairment of inventory)
2
Gross profit
1,132,672
(460,746)
473,551
(517,346)
671,926
(43,795)
Research and development tax incentive and other income
3
1,893,782
1,167,984
Research and development expenses
Administration and corporate expenses
Finance costs
4
5
(3,591,156)
(2,039,467)
(57,133)
(2,117,263)
(2,428,131)
(15,356)
(3,122,048)
(3,436,561)
-
-
(3,122,048)
(3,436,561)
-
-
(3,122,048)
(3,436,561)
Cents
Cents
Loss before income tax expense
Income tax expense
Loss after income tax expense for the year attributable to the owners of Avecho
Biotechnology Limited
Other comprehensive loss for the year, net of tax
Total comprehensive loss for the year attributable to the owners of Avecho
Biotechnology Limited
Basic losses per share
Diluted losses per share
(0.10)
(0.10)
(0.15)
(0.15)
The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the
accompanying notes
4
Avecho Biotechnology Limited
Consolidated statement of financial position
As at 31 December 2024
Consolidated
31 December 31 December
Note
2024
2023
$
$
Assets
Current assets
Cash and cash equivalents
Trade and other receivables
Inventories
Other current assets
Total current assets
2,374,534
2,246,461
137,459
51,823
4,810,277
5,504,396
1,099,563
97,117
302,566
7,003,642
80,133
90,651
15,730
186,514
147,305
168,363
315,668
4,996,791
7,319,310
212,885
978,443
83,753
435,314
1,710,395
181,952
158,376
76,926
426,061
843,315
14,472
2,186
16,658
98,225
98,225
Total liabilities
1,727,053
941,540
Net assets
3,269,738
6,377,770
6
Non-current assets
Plant and equipment
Right-of-use assets
Other assets
Total non-current assets
Total assets
Liabilities
Current liabilities
Trade and other payables
Contract liabilities
Borrowings
Lease liabilities
Provisions
Total current liabilities
7
8
Non-current liabilities
Lease liabilities
Provisions
Total non-current liabilities
Equity
Issued capital
Reserves
Accumulated losses
9
Total equity
244,605,505 244,605,505
28,055,984
29,212,656
(269,391,751) (267,440,391)
3,269,738
6,377,770
The above consolidated statement of financial position should be read in conjunction with the accompanying notes
5
Avecho Biotechnology Limited
Consolidated statement of changes in equity
For the year ended 31 December 2024
Issued
capital
$
Consolidated
Balance at 1 January 2023
Accumulated
losses
Total equity
$
$
Reserves
$
237,528,800
29,000,426 (264,104,330)
2,424,896
Loss after income tax expense for the year
Other comprehensive loss for the year, net of tax
-
-
(3,436,561)
-
(3,436,561)
-
Total comprehensive loss for the year
-
-
(3,436,561)
(3,436,561)
7,286,705
(210,000)
102,730
(100,500)
210,000
100,500
-
7,286,705
102,730
-
29,212,656 (267,440,391)
6,377,770
Transactions with owners in their capacity as owners:
Contributions of equity, net of transaction costs
Share-based payments
Share options lapsed
Issue of broker options
Balance at 31 December 2023
244,605,505
Issued
capital
$
Consolidated
Balance at 1 January 2024
Accumulated
losses
Total equity
$
$
Reserves
$
244,605,505
29,212,656 (267,440,391)
6,377,770
Loss after income tax expense for the year
Other comprehensive loss for the year, net of tax
-
-
(3,122,048)
-
(3,122,048)
-
Total comprehensive loss for the year
-
-
(3,122,048)
(3,122,048)
Transactions with owners in their capacity as owners:
Share-based payments
Share options lapsed
-
14,016
(1,170,688)
1,170,688
14,016
-
28,055,984 (269,391,751)
3,269,738
Balance at 31 December 2024
244,605,505
The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes
6
Avecho Biotechnology Limited
Consolidated statement of cash flows
For the year ended 31 December 2024
Consolidated
31 December 31 December
2024
2023
$
$
Cash flows from operating activities
Receipts from customers (inclusive of GST)
Receipts from R&D tax incentive and Export Market Development Grants
Payments to suppliers and employees (inclusive of GST)
Finance costs paid
Interest received
566,234
1,066,298
(5,655,323)
(7,538)
61,611
758,215
723,888
(4,686,095)
(11,479)
35,516
Net cash used in operating activities
(3,968,718)
(3,179,955)
Cash flows from investing activities
Payments for security deposits
(15,730)
-
Net cash used in investing activities
(15,730)
-
Cash flows from financing activities
Proceeds from issue of shares
Costs paid for issue of shares
Payment of principal element of lease liabilities
Receipts from borrowings
(76,926)
931,512
8,003,594
(716,529)
(70,924)
-
Net cash from financing activities
854,586
7,216,141
Net (decrease)/ increase in cash and cash equivalents
Cash and cash equivalents at the beginning of the financial year
(3,129,862)
5,504,396
4,036,186
1,468,210
Cash and cash equivalents at the end of the financial year
2,374,534
5,504,396
The above consolidated statement of cash flows should be read in conjunction with the accompanying notes
7
Avecho Biotechnology Limited
Notes to the consolidated financial statements
31 December 2024
Note 1. Basis of preparation
This preliminary final report has been prepared in accordance with ASX Listing Rule 4.3A and the disclosure requirements of
ASX Appendix 4E.
These preliminary financial statements do not include all the notes of the type normally included in annual financial statements.
Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 31 December
2023 and any public announcements made by the Avecho Biotechnology Limited during the year ended 31 December 2024
in accordance with the continuous disclosure requirements of the Corporations Act 2001 and the Australian Securities
Exchange Listing Rules.
The principal accounting policies adopted in the preparation of the financial statements are consistent with those disclosed in
annual financial statements for the year ended 31 December 2023. These policies have been consistently applied to all the
years presented, unless otherwise stated.
Historical cost convention
The financial statements have been prepared under the historical cost convention, except for, where applicable, the
revaluation of financial assets and liabilities at fair value through profit or loss, financial assets at fair value through other
comprehensive income, investment properties, certain classes of property, plant and equipment and derivative financial
instruments.
Note 2. Revenue from contracts with customers
Consolidated
31 December 31 December
2024
2023
$
$
Sale of goods transferred at a point in time
1,132,672
473,551
Note 3. Research and development tax incentive and other income
Consolidated
31 December 31 December
2024
2023
$
$
Net foreign exchange gain
Research and development tax incentive
Export Market Development Grants (EMDG)
Project income
Other
Interest income
35,456
1,635,464
158,376
2,875
61,611
20,301
1,075,567
36,600
35,516
1,893,782
1,167,984
Note 4. Research and development expenses
Consolidated
31 December 31 December
2024
2023
$
$
Consultancy and laboratory consumables
Clinical development expenses
Employment expenses associated with research and development
8
55,771
2,866,847
668,538
33,273
1,434,144
649,846
3,591,156
2,117,263
Avecho Biotechnology Limited
Notes to the consolidated financial statements
31 December 2024
Note 5. Administration and corporate expenses
Consolidated
31 December 31 December
2024
2023
$
$
Professional and consultancy fees
Insurance
Patent portfolio expenses
Salaries and other employee expenses (non - R&D)
Director fees
Superannuation expenses
Share based payments expenses
Shareholder and listing expenses
Depreciation of right-of-use assets and plant and equipment
Amortisation of intangible assets
Occupancy expenses
Other sundry expenses
434,076
339,902
231,858
199,645
247,678
118,388
14,017
167,012
144,885
52,716
89,290
600,023
343,140
297,496
267,637
210,500
102,936
102,730
190,924
152,445
26,250
134,050
2,039,467
2,428,131
Note 6. Trade and other receivables
Consolidated
31 December 31 December
2024
2023
$
$
Current assets
Trade receivables
R&D tax incentive credit receivable
Other receivables
569,311
-
1,645,372
31,778
1,677,150
1,076,206
23,357
1,099,563
2,246,461
1,099,563
Fair value and credit risk
Due to the short term nature of these receivables, their carrying value is assumed to approximate their fair value. The maximum
exposure to credit risk is the fair value of receivables.
Note 7. Trade and other payables
Consolidated
31 December 31 December
2024
2023
$
$
Current liabilities
Trade payables
Accrued expenses
Other payables
9
60,634
128,155
24,096
94,903
63,500
23,549
212,885
181,952
Avecho Biotechnology Limited
Notes to the consolidated financial statements
31 December 2024
Note 8. Borrowings
Consolidated
31 December 31 December
2024
2023
$
$
Current liabilities
R&D Incentive loan
978,443
-
The Company entered into a R&D Advance Facility agreement with Endpoints Capital, to advance on the Company’s 2024
R&D tax incentive. Repayment of the amounts advanced from Endpoints Capital coincide with receipt of R&D tax incentives
and incur interest at 15.8% per annum. The facility is secured against the Company's 2024 R&D tax incentive.
Note 9. Issued capital
31 December
2024
Shares
Ordinary shares - fully paid
Consolidated
31 December 31 December
2023
2024
Shares
$
3,169,297,013 3,169,297,013
10
244,605,505
31 December
2023
$
244,605,505
Share your feedback
Discover